Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sonnet Biotherapeutics Holdings Inc (NQ: SONN ) 4.890 +0.190 (+4.04%) Streaming Delayed Price Updated: 10:41 AM EDT, Oct 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Sonnet Biotherapeutics Holdings Inc < Previous 1 2 3 Next > Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update August 14, 2024 From Sonnet BioTherapeutics Holdings, Inc. Via GlobeNewswire Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study July 24, 2024 From Sonnet BioTherapeutics Holdings, Inc. Via GlobeNewswire Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds June 20, 2024 From Sonnet BioTherapeutics Holdings, Inc. Via GlobeNewswire Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview October 31, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain June 13, 2024 From Sonnet BioTherapeutics Holdings, Inc. Via GlobeNewswire Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting May 28, 2024 From Sonnet BioTherapeutics Holdings, Inc. Via GlobeNewswire Sonnet BioTherapeutics Announces Review of Strategic Alternatives May 22, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target May 20, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update May 14, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference May 06, 2024 Via ACCESSWIRE Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting March 19, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective March 11, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers February 29, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update February 14, 2024 Via ACCESSWIRE Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy December 21, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update December 14, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering October 25, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting October 17, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology September 20, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance September 19, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split August 31, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US August 16, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update August 14, 2023 Via ACCESSWIRE Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference July 31, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement June 28, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy June 23, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab June 20, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update May 10, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting April 18, 2023 Via ACCESSWIRE Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting April 17, 2023 Via ACCESSWIRE < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.